Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Avastin packshot

UK pharma teams up for better cancer drug access

September 20, 2013
Medical Communications, Sales and Marketing Cancer Drugs Fund, NICE, Novartis, Roche, Sanofi, avastin, no

News
nice_sign

NICE: we need more Aubagio data

September 18, 2013
Sales and Marketing Aubagio, Genzyme, MS, NICE, Sanofi

News
NICE image

NICE queries pharma R&D costs

September 5, 2013
Research and Development, Sales and Marketing Dillon, NICE, Pfizer, R&D

NICE has questioned whether pharma really spends as much as it says it does on bringing new treatments to market …

News
NICE image

Rare disease drugs ‘need separate budget’

September 3, 2013
Research and Development, Sales and Marketing NHS, NICE, rare diseases

A group of MPs in the UK are calling for a ring-fenced fund to pay for drugs for rare and …

News
nice_sign

ThromboGenics/Novartis’ Jetrea gains NICE ‘yes’

August 30, 2013
Alcon, Jetrea, NICE, Novartis, ThromboGenics

News

Afinitor too costly for NICE despite price cut

August 29, 2013
Sales and Marketing Afinitor, HER2 negative, NICE, Novartis, breast cancer

News
NICE image

‘Inequality’ for Welsh cancer patients

August 28, 2013
Sales and Marketing CDF, Cancer, England, NHS, NICE, Wales

Cancer sufferers in England are four times more likely to receive newer treatments on the NHS than patients in Wales, …

News
xalkori image

Price cut not enough for Pfizer’s Xalkori

August 16, 2013
Sales and Marketing NICE, Pfizer, Xalkori, lung cancer

In final draft guidance NICE has rejected Pfizer’s new lung cancer drug Xalkori because of its high cost. The Institute …

News
NICE image

AllTrials campaign releases manifesto

August 9, 2013
Medical Communications, Research and Development, Sales and Marketing Bad pharma, GSK, Goldacre, NICE, transparency

The UK clinical trial transparency initiative AllTrials has released its first detailed manifesto as it looks to ramp up pressure …

News
Perjeta image

Roche breast cancer drug Perjeta rejected by NICE

August 6, 2013
Sales and Marketing Cancer, NICE, Perjeta, Roche

NICE is not recommending Roche’s next generation breast cancer drug Perjeta as a treatment for a particular type of advanced …

News
finbarr-martin-bw

Two non-executive directors join NICE Board

July 26, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing DoH, NICE, finbarr martin, mumford

The Department of Health has announced that two new non-executive directors will join the National Institute for Health and Care …

Appointment
Benlysta image

Benlysta once again rejected by NICE

July 25, 2013
Sales and Marketing Benlysta, GSK, NHS, NICE

NICE has opened a second public consultation for GSK’s lupus drug Benlysta after the Institute has again rejected the medicine …

News
Mabthera image

NICE ‘no’ for MabThera

July 23, 2013
Sales and Marketing MabThera, NHS, NICE, Roche

Roche has been dealt a blow by NICE, with the health watchdog deciding that MabThera should not be used on …

News
pfizer image

NICE rejects Pfizer blood cancer drug

July 16, 2013
Sales and Marketing BMS, CML, NICE, Pfizer, bosulif

NICE is not recommending Pfizer’s blood cancer drug Bosulif due to uncertainties over its cost effectiveness and survival benefit. In …

News
Celgene image

NICE no for Celgene’s Revlimid

July 11, 2013
Sales and Marketing Celgene, NICE, Revlimid

NICE has issued new draft guidance not recommending Celgene’s bone marrow disorder drug Revlimid over uncertainties of its efficacy. Revlimid …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026